Krebs Biochemicals Peer Comparison
NSE: KREBSBIO | BSE: 524518
₹55.95
₹1.45
(2.66%)
As on 04-Sep-2026 15:59IST
Market cap
₹121 Cr
Revenue (TTM)
₹25 Cr
P/E Ratio
--
P/B Ratio
-0.7
Div. Yield
0 %
Edit
| Krebs Biochemicals | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
121 | 36,584 | 29,051 | 16,782 | 15,009 |
Revenue (₹ Cr) |
25 | 9,683 | 2,372 | 2,590 | 676 |
Net Profit (₹ Cr) |
-14.10 | 1,018.97 | 497.77 | 603.02 | 183.60 |
Net Margin (%) |
-51.43 | 10.47 | 20.72 | 22.63 | 26.06 |
RoE (%) |
-- | 21.30 | 28.49 | 19.61 | 22.72 |
Price to Earnings |
-- | 36.17 | 58.36 | 27.83 | 82.18 |
Price-To-Book |
-0.73 | 6.99 | 14.37 | 4.82 | 16.25 |
Income Statement (₹ Cr)
| Krebs Biochemicals | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Operating Revenue
|
25.23 | 9,683.45 | 2,371.81 | 2,590.40 | 675.61 |
|
Total Income
|
27.41 | 9,730.84 | 2,402.61 | 2,664.23 | 704.48 |
|
Total Expenditure
|
27.77 | 7,739.53 | 1,608.91 | 1,753.71 | 442.67 |
|
EBITDA
|
-2.54 | 1,943.92 | 762.90 | 836.69 | 232.94 |
|
Depreciation
|
6.41 | 425.10 | 98.11 | 78.88 | 15.56 |
|
EBIT
|
-8.95 | 1,518.82 | 664.79 | 757.81 | 217.38 |
|
Interest
|
7.32 | 148.45 | 26.33 | 5.43 | 7.96 |
|
Other Income
|
2.17 | 47.39 | 30.80 | 73.83 | 28.87 |
|
Exceptional Items
|
0.00 | -27.85 | 0.00 | -25.66 | 0.00 |
|
Profit before Tax
|
-14.10 | 1,389.91 | 669.26 | 800.55 | 238.30 |
|
Provision for Tax
|
0.00 | 370.94 | 171.48 | 197.53 | 54.69 |
|
Profit after Tax
|
-14.10 | 1,018.97 | 497.77 | 603.02 | 183.60 |
Liabilities (₹ Cr)
| Krebs Biochemicals | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-162.75 | 4,950.03 | 1,874.47 | 3,332.13 | 883.34 |
|
Minority Interest
|
0.00 | -7.58 | 0.00 | 0.00 | -0.97 |
|
Non-Current Liabilities
|
212.94 | 723.57 | 345.47 | 142.73 | 74.82 |
|
Current Liabilities
|
113.07 | 3,912.24 | 710.20 | 508.04 | 201.96 |
|
Total Liabilities
|
169.04 | 8,121.73 | 2,179.88 | 3,753.59 | 716.85 |
Assets (₹ Cr)
| Krebs Biochemicals | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
143.30 | 3,392.16 | 1,290.62 | 1,321.38 | 477.92 |
|
Current Assets
|
9.62 | 5,612.10 | 1,483.13 | 2,649.36 | 623.97 |
|
Total Assets
|
169.04 | 8,121.73 | 2,179.88 | 3,753.59 | 716.85 |
|
Total Debt*
|
212.21 | 731.70 | 136.01 | 0.00 | 135.25 |
|
Net Current Assets
|
-103.44 | 1,699.86 | 772.93 | 2,141.33 | 422.01 |
|
Contingent Liabilities
|
9.26 | 393.94 | 8.97 | 4.82 | 0.10 |
Cashflow (₹ Cr)
| Krebs Biochemicals | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-7.89 | 851.71 | 317.40 | 391.52 | 48.73 |
|
Cash Flow from Investing Activities
|
-4.97 | -94.00 | -298.16 | -615.65 | -78.76 |
|
Cash from Financing Activities
|
12.86 | -813.96 | 24.96 | -6.23 | 52.70 |
|
Net Cash Inflow / Outflow
|
0.00 | -56.25 | 44.21 | -230.35 | 22.67 |
Ratios
Profitability Ratios
| Krebs Biochemicals | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-29.92 | 22.49 | 23.45 | 25.50 | 35.83 |
|
ROE (%)
|
0.00 | 21.30 | 28.49 | 19.61 | 22.72 |
|
ROA (%)
|
-8.48 | 11.42 | 19.48 | 16.31 | 31.25 |
|
EBIT Margin (%)
|
-35.47 | 15.68 | 28.03 | 29.25 | 32.18 |
|
Net Margin (%)
|
-51.43 | 10.47 | 20.72 | 22.63 | 26.06 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Krebs Biochemicals | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-29.72 | 18.36 | 78.33 | 7.93 | 23.56 |
|
EBIT Growth (%)
|
58.40 | 30.43 | 303.07 | 19.88 | 12.00 |
|
Net Profit Growth (%)
|
47.97 | 32.39 | 182.61 | 21.66 | 20.07 |
|
EPS Growth (%)
|
47.97 | 36.68 | 277.72 | 25.42 | 50.65 |
|
Book Value Growth (%)
|
-22.67 | 50.94 | 18.89 | 20.94 | 37.86 |
Valuation Ratios
| Krebs Biochemicals | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-8.57 | 35.43 | 58.36 | 26.95 | 78.98 |
|
Price / Book Value
|
-0.73 | 6.99 | 14.37 | 4.82 | 16.25 |
|
Dividend Yield (%)
|
0.00 | 0.19 | 0.15 | 0.37 | 0.11 |
|
EV/EBITDA
|
-131.18 | 19.36 | 37.87 | 19.12 | 64.58 |
|
Market Cap (₹ Cr)
|
144.00 | 20,327.45 | 15,494.53 | 13,228.83 | 0.00 |
Solvency Ratios
| Krebs Biochemicals | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-1.00 | 0.05 | 0.09 | 0.00 | 0.04 |
|
Short term debt to equity ratio
|
-0.35 | 0.11 | -- | -- | 0.17 |
|
Current Ratio
|
0.09 | 1.43 | 2.09 | 5.21 | 3.09 |
|
Quick Ratio
|
0.03 | 0.82 | 1.37 | 3.85 | 2.02 |
|
Interest Coverage
|
-0.93 | 10.36 | 26.41 | 148.49 | 30.94 |
Operating Efficiency Ratios
| Krebs Biochemicals | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
0.02 | 26.46 | 22.82 | 41.42 | 33.68 |
|
Asset Turnover
|
0.15 | 1.09 | 0.93 | 0.70 | 1.15 |
|
Receivable days
|
8.23 | 87.83 | 85.17 | 132.12 | 114.95 |
|
Inventory Days
|
66.69 | 78.64 | 90.97 | 102.08 | 68.03 |
|
Payable days
|
1,219.44 | 174.97 | 137.94 | 133.54 | 133.44 |
|
Cash Conversion Cycle
|
-1,144.52 | -8.50 | 38.21 | 100.66 | 49.53 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
